Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.

W Fried, Michael; Buti, Maria; J Dore, Gregory; Flisiak, Robert; Ferenci, Peter; Jacobson, Ira; Marcellin, Patrick; Manns, Michael; Nikitin, Igor; Poordad, Fred; Sherman, Morris; Zeuzem, Stefan; Scott, Jane; Gilles, Leen; Lenz, Oliver; Peeters, Monika; Sekar, Vanitha; De Smedt, Goedele; Beumont-Mauviel, Maria

doi:10.1002/hep.26641

Public

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.

Shared by NobleBlocks on Dec 1, 2013 • 12:00 AM UTC

Authors:

Michael W Fried

Maria Buti

Gregory J Dore

Abstract

The phase IIb, double-blind, placebo-controlled PILLAR trial investigated the efficacy and safety of two different simeprevir (SMV) doses administered once-daily (QD) with pegylated interferon (Peg-IFN)-α-2a and ribavirin (RBV) in treatment-naïve patients with HCV genotype 1 infection. Patients were...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!